Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 15,628 shares at $451.51 ($7.1M) on 2025-11-17, disclosed to the SEC on 2025-11-19.
Scheduled sale ($7.1M) by CSO & EVP, Head of Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $449.00 | 8,168 | $3.7M | 51.7% |
| 2 | $450.09 | 96 | $43K | 0.6% |
| 3 | $451.51 | 129 | $58K | 0.8% |
| 4 | $451.51 | 129 | $58K | 0.8% |
| 5 | $455.24 | 368 | $168K | 2.4% |
| 6 | $455.24 | 368 |
| $168K |
| 2.4% |
| 7 | $456.25 | 364 | $166K | 2.3% |
| 8 | $457.39 | 262 | $120K | 1.7% |
| 9 | $457.39 | 262 | $120K | 1.7% |
| 10 | $458.41 | 794 | $364K | 5.1% |
| 11 | $458.41 | 794 | $364K | 5.1% |
| 12 | $459.89 | 622 | $286K | 4.0% |
| 13 | $459.89 | 622 | $286K | 4.0% |
| 14 | $460.84 | 707 | $326K | 4.6% |
| 15 | $460.84 | 707 | $326K | 4.6% |
| 16 | $461.96 | 323 | $149K | 2.1% |
| 17 | $461.96 | 323 | $149K | 2.1% |
| 18 | $463.08 | 295 | $137K | 1.9% |
| 19 | $463.08 | 295 | $137K | 1.9% |
| Total | $453.75 avg | 15,628 | $7.1M | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $1.3M | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-10-03 | $2.1M | — | Filing → |